Navigation Links
Allison shares inaugural Tang Prize for his cancer immunotherapy innovation

The first Tang Prize for Biopharmaceutical Science has been awarded to Jim Allison, Ph.D., chair of Immunology at The University of Texas MD Anderson Cancer Center and Tasuku Honjo, M.D., Ph.D., of Japan's Kyoto University for their research leading to cancer immunotherapy.

"Both scholars' discoveries have opened a new therapeutic era in medicine," said Lee Yuan-tseh, Ph.D., Taiwan's winner of the 1986 Nobel Prize in chemistry, at the award announcement in Taipei, Taiwan, this week.

Taiwanese entrepreneur Samuel Yin established the biennial Tang Prize in December 2012. The 2014 prizes provide a cash award of NT$40 million ($1.3 million) and research grant of NT$10 million.

Allison launched an entirely new way to treat cancer by blocking molecules on immune system T cells that turn off immune response. The treatment, called immune checkpoint blockade, grew out of his basic science research to understand the biology of T cells the immune system's customized attackers.

"Receiving the Tang Prize is a great honor for me, as well as recognition of the growing importance of cancer immunotherapy," Allison said.

Allison developed an antibody to block CTLA-4, an off-switch on T cells, to unleash immune attack on tumors. Ipilimumab, a drug based on his antibody, has extinguished untreatable late-stage melanoma in 22 percent of patients in clinical trials for three years or longer, unprecedented results. The U.S. Food and Drug Administration approved the drug, now called Yervoy, for metastatic melanoma in 2011. Honjo discovered the second immune checkpoint on T cells, called PD1. A variety of experimental drugs to block PD1 and its activating ligand, PD-L1, are showing great promise in clinical trials.

Allison and Honjo were selected from hundreds of international nominees for the award, which recognizes original research that has led to significant advances in preventing, diagnosing and treating major human diseases. Academia Sinica, Taiwan's preeminent academic organization, similar to the National Academy of Sciences in the United States, administered award selection.

Immune checkpoint blockade therapy is spreading to other types of cancers through clinical trials. Researchers are studying how these drugs work in combination with targeted therapies, chemotherapy and each other as well as why they only work for some patients.

Allison is executive director of MD Anderson's immunotherapy platform, which addresses these questions and supports immunotherapy research across multiple cancer types, including the Moon Shots Program, established in 2012 to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths.

Allison also is deputy director of the David H Koch Center for Applied Research of Genitourinary Cancers and holds the Vivian L. Smith Distinguished Chair in Immunology at MD Anderson.


Contact: Scott Merville
University of Texas M. D. Anderson Cancer Center

Related medicine news :

1. Cancer immunotherapy leader Allison to receive 2014 Szent-Gyorgyi Prize
2. MD Anderson researcher Jim Allison wins Breakthrough Prize for his innovative cancer immunology rese
3. Allison Kennedy Zeitlin & Company Realtors Hosts Gentle Carousel Mini Therapy Horses
4. The Economist honors cancer immunotherapy pioneer James Allison
5. T cell biology pioneer Allison wins first AACR honor for cancer immunology
6. Forbes Living TV Host Forbes Riley Shares Top Rated House Wares
7. Victory Over Violence: New Book, "Traveling with the Life-Giver" Shares How to Heal After Domestic Abuse
8. New Book "Donald's Story" Shares How to Caregive While Managing Business and Home Life
9. New Book "This Life's Tempestuous Sea" Shares How Fixing Social Problems Can Improve Health
10. Mold Shuts Down 8 Loughman Oaks Elementary School Classrooms, My Cleaning Products Shares Mold Removal Tip How Others Could Prevent Same Problem
11. “Tips To Become A Patient Person,” a New Article on Vkool.Com, Shares Tips with People on How to Be More Patient - V-kool
Post Your Comments:
Related Image:
Allison shares inaugural Tang Prize for his cancer immunotherapy innovation
(Date:11/27/2015)... ... , ... CBD College is proud to announce that on November ... to its Diagnostic Medical Sonography program. CBD College is honored to join this very ... and universities in the state of California make the cut. CBD College is officially ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer and ... of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. ... 5.10 up-to-date with a version of Asterisk that will receive not only security ...
(Date:11/26/2015)... ... November 26, 2015 , ... Somu Sivaramakrishnan announced today that ... Somu now offers travelers, value and care based Travel Services, including exclusive pricing ... well as, cabin upgrades and special amenities such as, shore excursions, discounted fares, ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... medical opinion process, participated in the 61st annual Employee Benefits Conference. The Employee ... took place Sunday, November 8th through Wednesday, November 11th, 2015. The conference was ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... potentially more aggressive than those found on mammography, according to a study published ... of additional cancers not seen on mammography may necessitate a change in treatment. ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... the "Radioimmunoassay Market by Type (Reagents ... Industry, Academics, Clinical Diagnostic Labs), Application (Research, ... to 2020" report to their offering. ... the addition of the "Radioimmunoassay Market ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
(Date:11/25/2015)... ATLANTA , Nov. 25, 2015 ... the first federal bellwether trial against Wright Medical ... relating to their Conserve metal-on-metal hip implant device, ... Christiansen.  Following a two week trial and three ... Conserve metal-on-metal hip device was defectively designed and ...
Breaking Medicine Technology: